Sernova Corp.
Developer of an implantable bio-hybrid organ platform and associated regenerative cell therapies aimed at restoring physiologic function for patients with type 1 diabetes and other chronic diseases. Activities described on the site include platform engineering, development of blood-derived induced pluripotent stem cell therapies with external partners, ongoing Phase 1/2 clinical trials, partnership development, and investor and regulatory reporting.
Industries
N/A
Nr. of Employees
small (1-50)
Sernova Corp.
700 Collip Circle, Ste 114, London, ON, Canada N6G 4X8
Products
Implantable bio-hybrid organ for therapeutic cell delivery
An implantable device platform engineered to host therapeutic cells and support restoration of physiologic function in patients deficient in specific hormones or factors.
Implantable bio-hybrid organ for therapeutic cell delivery
An implantable device platform engineered to host therapeutic cells and support restoration of physiologic function in patients deficient in specific hormones or factors.
Services
Sponsor and operational support for Phase 1/2 clinical studies of implanted cell therapies.
Collaborative development agreements with external partners to advance cell sources and manufacturing for therapeutic programs.
Sponsor and operational support for Phase 1/2 clinical studies of implanted cell therapies.
Collaborative development agreements with external partners to advance cell sources and manufacturing for therapeutic programs.
Expertise Areas
- Regenerative medicine and cell therapy development
- Implantable medical device platform development
- Induced pluripotent stem cell (iPSC) sourcing and differentiation
- Early-phase clinical trial management (Phase 1/2)
Key Technologies
- Implantable bio-hybrid organ platform
- Induced pluripotent stem cells (iPSC)-derived therapeutics
- Cell therapy implantation
- Early-phase clinical trial methodologies
News & Updates
Company annual general meeting and shareholder event.
Virtual investor event featuring company leadership.
Public update on the ongoing Phase 1/2 clinical trial of the implantable bio-hybrid organ for treatment of type 1 diabetes.
Press release reporting positive interim data from the ongoing Phase 1/2 clinical trial of the implantable bio-hybrid organ in patients with type 1 diabetes.
Announcement of a collaboration with an external pharmaceutical company to advance development toward a functional cure for type 1 diabetes.
Company reported positive interim data from an ongoing Phase 1/2 clinical trial of its implantable bio-hybrid organ in patients with type 1 diabetes.
Company annual general meeting and shareholder event.
Virtual investor event featuring company leadership.
Public update on the ongoing Phase 1/2 clinical trial of the implantable bio-hybrid organ for treatment of type 1 diabetes.
Press release reporting positive interim data from the ongoing Phase 1/2 clinical trial of the implantable bio-hybrid organ in patients with type 1 diabetes.
Announcement of a collaboration with an external pharmaceutical company to advance development toward a functional cure for type 1 diabetes.
Company reported positive interim data from an ongoing Phase 1/2 clinical trial of its implantable bio-hybrid organ in patients with type 1 diabetes.